GlassScriptPhysician profile
Sarah Ann Williams
NPI 1528542818
$2,796.80
in general payments reported to CMS, 2019-2025
38 companies · $56.76 in 2025
The $56.76 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,321 · 2022: $274 · 2023: $117 · 2024: $28.13 · 2025: $56.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $201.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $542.55 | 2021 | |
| Abbvie INC. | $380.99 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $249.47 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $207.61 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $166.08 | 2021 | |
| Ucb, INC. | $145.61 | 2021 | |
| Lundbeck LLC | $68.77 | 2021 | |
| Upsher-Smith Laboratories LLC | $65.01 | 2021 | |
| Genzyme Corporation | $63.03 | 2021 | |
| Sunovion Pharmaceuticals INC. | $60.02 | 2021 | |
| Janssen Pharmaceuticals, INC | $59.62 | 2021 | |
| Eisai INC. | $55.84 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $54.60 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $49.69 | 2021 | |
| Emd Serono, INC. | $46.38 | 2021-2023 | Mavenclad |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $45.85 | 2023 | Vivitrol |
| Supernus Pharmaceuticals, INC. | $42.90 | 2021 | |
| Medtronic, INC. | $42.83 | 2021 | |
| Livanova USA, INC. | $42.29 | 2021 | |
| Csl Behring | $38.92 | 2021 | |
| Acorda Therapeutics, INC | $34.03 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $33.30 | 2021 | |
| Almatica Pharma LLC | $30.16 | 2021 | |
| Pfizer INC. | $27.95 | 2021 | |
| Allergan, INC. | $26.49 | 2021 | |
| Lilly USA, LLC | $24.89 | 2021 | |
| Sk Life Science, INC. | $23.22 | 2021 | |
| Alnylam Pharmaceuticals INC. | $19.43 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.21 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.16 | 2025 | Fruzaqla |
| Jazz Pharmaceuticals INC. | $17.36 | 2021 | |
| Boston Scientific Corporation | $15.96 | 2021 | |
| Nalu Medical, INC. | $15.51 | 2021 | |
| Currax Pharmaceuticals LLC | $14.26 | 2021 | |
| Biodelivery Sciences International, INC. | $13.12 | 2021 | |
| Neurocrine Biosciences, INC. | $12.81 | 2021 | |
| Vanda Pharmaceuticals INC. | $12.51 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.